Background: This study investigated the effects of metformin and weight loss on biomarkers associated with breast cancer prognosis. Methods: Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomly assigned to metformin vs placebo and to a weight loss intervention vs control (ie, usual care). The 2 × 2 factorial design allows a single randomized trial to investigate the effect of two factors and interactions between them. Outcomes were changes in fasting insulin, glucose, C-reactive protein (CRP), estradiol, testosterone, and sex-hormone binding globulin (SHBG). The trial was powered for a main effects analysis of metformin vs placebo and weight loss vs control. All tests of statistical significance were two-sided. Results:A total of 313 women (94.0%) completed the six-month trial. High prescription adherence (ie, ≥80% of pills taken) ranged from 65.9% of participants in the metformin group to 81.3% of those in the placebo group (P < .002). Mean percent weight loss was statistically significantly higher in the weight loss group (-5.5%, 95% confidence interval [CI] = -6.3% to -4.8%) compared with the control group (-2.7%, 95% CI = -3.5% to -1.9%). Statistically significant group differences (ie, percent change in metformin group minus placebo group) were -7.9% (95% CI = -15.0% to -0.8%) for insulin, -10.0% (95% CI = -18.5% to -1.5%) for estradiol, -9.5% (95% CI = -15.2% to -3.8%) for testosterone, and 7.5% (95% CI = 2.4% to 12.6%) for SHBG. Statistically significant group differences (ie, percent change in weight loss group minus placebo group) were -12.5% (95% CI = -19.6% to -5.3%) for insulin and 5.3% (95% CI = 0.2% to 10.4%) for SHBG. Conclusions: As adjuvant therapy, weight loss and metformin were found to be a safe combination strategy that modestly lowered estrogen levels and advantageously affected other biomarkers thought to be on the pathway for reducing breast cancer recurrence and mortality.
RCT Entities:
Background: This study investigated the effects of metformin and weight loss on biomarkers associated with breast cancer prognosis. Methods: Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomly assigned to metformin vs placebo and to a weight loss intervention vs control (ie, usual care). The 2 × 2 factorial design allows a single randomized trial to investigate the effect of two factors and interactions between them. Outcomes were changes in fasting insulin, glucose, C-reactive protein (CRP), estradiol, testosterone, and sex-hormone binding globulin (SHBG). The trial was powered for a main effects analysis of metformin vs placebo and weight loss vs control. All tests of statistical significance were two-sided. Results: A total of 313 women (94.0%) completed the six-month trial. High prescription adherence (ie, ≥80% of pills taken) ranged from 65.9% of participants in the metformin group to 81.3% of those in the placebo group (P < .002). Mean percent weight loss was statistically significantly higher in the weight loss group (-5.5%, 95% confidence interval [CI] = -6.3% to -4.8%) compared with the control group (-2.7%, 95% CI = -3.5% to -1.9%). Statistically significant group differences (ie, percent change in metformin group minus placebo group) were -7.9% (95% CI = -15.0% to -0.8%) for insulin, -10.0% (95% CI = -18.5% to -1.5%) for estradiol, -9.5% (95% CI = -15.2% to -3.8%) for testosterone, and 7.5% (95% CI = 2.4% to 12.6%) for SHBG. Statistically significant group differences (ie, percent change in weight loss group minus placebo group) were -12.5% (95% CI = -19.6% to -5.3%) for insulin and 5.3% (95% CI = 0.2% to 10.4%) for SHBG. Conclusions: As adjuvant therapy, weight loss and metformin were found to be a safe combination strategy that modestly lowered estrogen levels and advantageously affected other biomarkers thought to be on the pathway for reducing breast cancer recurrence and mortality.
Authors: Elizabeth A Walker; Mark Molitch; M Kaye Kramer; Steven Kahn; Yong Ma; Sharon Edelstein; Kellie Smith; Mariana Kiefer Johnson; Abbas Kitabchi; Jill Crandall Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: Christopher R Friese; T May Pini; Yun Li; Paul H Abrahamse; John J Graff; Ann S Hamilton; Reshma Jagsi; Nancy K Janz; Sarah T Hawley; Steven J Katz; Jennifer J Griggs Journal: Breast Cancer Res Treat Date: 2013-03-31 Impact factor: 4.872
Authors: Mary C Playdon; Michael B Bracken; Tara B Sanft; Jennifer A Ligibel; Maura Harrigan; Melinda L Irwin Journal: J Natl Cancer Inst Date: 2015-09-30 Impact factor: 13.506
Authors: Cesar A Santa-Maria; Janelle W Coughlin; Dipali Sharma; Mary Armanios; Amanda L Blackford; Colleen Schreyer; Arlene Dalcin; Ashley Carpenter; Gerald J Jerome; Deborah K Armstrong; Madhu Chaudhry; Gary I Cohen; Roisin M Connolly; John Fetting; Robert S Miller; Karen L Smith; Claire Snyder; Andrew Wolfe; Antonio C Wolff; Chiung-Yu Huang; Lawrence J Appel; Vered Stearns Journal: Clin Cancer Res Date: 2020-02-18 Impact factor: 12.531
Authors: Sheri J Hartman; Sandahl H Nelson; Catherine R Marinac; Loki Natarajan; Barbara A Parker; Ruth E Patterson Journal: Psychooncology Date: 2019-06-27 Impact factor: 3.894
Authors: Melinda L Irwin; Diana Lowry; Marian L Neuhouser; Jennifer Ligibel; Kathryn Schmitz; Ruth E Patterson; Graham Colditz; Fangyong Li; Linda Nebeling Journal: Transl Behav Med Date: 2021-03-16 Impact factor: 3.046
Authors: Justin C Brown; Sui Zhang; Jennifer A Ligibel; Melinda L Irwin; Lee W Jones; Nancy Campbell; Michael N Pollak; Alexandra Sorrentino; Brenda Cartmel; Maura Harrigan; Sara M Tolaney; Eric P Winer; Kimmie Ng; Thomas A Abrams; Tara Sanft; Pamela S Douglas; Frank B Hu; Charles S Fuchs; Jeffrey A Meyerhardt Journal: Cancer Prev Res (Phila) Date: 2020-08-28
Authors: Tengteng Wang; Maryam S Farvid; Jae H Kang; Michelle D Holmes; Bernard A Rosner; Rulla M Tamimi; Walter C Willett; A Heather Eliassen Journal: Cancer Res Date: 2021-06-09 Impact factor: 12.701